Business, energy, technology, markets and global industry news from Business News Today

Tagrisso

PharmaDeviceNews Tagrisso
A representative image illustrating BlossomHill Therapeutics’ BH-30643 lung cancer program as the FDA grants Fast Track designation for the investigational therapy targeting EGFR C797S-positive non-small cell lung cancer after resistance to third-generation EGFR inhibitors.
Pharma & Biotech

What does RC220 dose escalation mean for Racura Oncology’s cancer drug pipeline?

Racura Oncology clears RC220 dose escalation to 100 mg/m² in its lung cancer trial. Examine the safety findings and next clinical milestones.

Read More
Abbisko Therapeutics and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated non-small cell lung cancer, putting safety, pneumonitis risk and treatment durability under close scrutiny. Representative image.
Pharma & Biotech

AstraZeneca adds Abbisko’s lumipodlin to expanding Tagrisso combination strategy

Discover why Abbisko and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated lung cancer.

Read More